Technology
The stack traditional CDMOs cannot match.
Single-use manufacturing
No cleaning-validation delays, lower contamination risk, and accessible CAPEX without stainless-steel infrastructure.
Automation & digitization
Magnetic-bead processes and continuous manufacturing workflows lower COGS and accelerate cycle times.
BSL-2 viral vector capacity
One of the few U.S. facilities purpose-built with BSL-2 capacity for gene and viral vector drug products.
Real-time data integration
E-documentation and integrated eClinical platforms produce IND-ready data packages with no manual reconciliation.
BSL-2 gene therapy programs are a specialty at LPB, not an afterthought.
Ecosystem
You’re not just getting a CDMO. You’re joining a network.
Preclinical R&D
Divine Myelin
Drug discovery, gap analyses, asset development plans.
Bioanalytical & QA
Celleqore
GxP bioanalytical testing, QC and QA services, FDA and EU expertise.
Growth & capital
Higgs Insights
Business rigor and data-driven execution to double investor interest and funding.
Clinical operations
CR Clinical
Global CRO with 1,000+ trial sites for trial execution and data capture.
Competition
The incumbents were not built for you.
| LucasPye Bio | Traditional CDMOs | |
|---|---|---|
| Total dev. lifecycle | 6–7 years | 12–15 years |
| Tech-transfer duration | 8 months | ~14 months |
| Single-use, BSL-2 capable | Yes | No |
| Digital, real-time workflows | Yes | No |
| Below-market price target | Yes | No |
Source: LucasPye Bio competitive framing, Preclinical Start-Up Packages (2026). Comparative data reflects public industry benchmarks.